Skip to main
ARDT

ARDT Stock Forecast & Price Target

ARDT Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 25%
Buy 42%
Hold 25%
Sell 8%
Strong Sell 0%

Bulls say

Ardent Health Inc reported a significant EBITDA of $143 million, marking a 46% year-over-year increase and improving its margin to 9.1%, which reflects a 240 basis point enhancement. The company also experienced a 2.9% growth in admissions, aligning with its full-year outlook, while contract labor costs improved and professional fees grew by 11% due to ongoing demand in anesthesia and radiology services. Overall, there are strong growth trends in the hospital sector, and Ardent's strategies in outpatient services indicate substantial opportunities for future earnings potential.

Bears say

Ardent Health Inc. reported an EBITDA of $143 million for the quarter, which, despite a year-over-year increase of 46%, fell 2% short of expectations due to a temporary boost from Kansas SDPs. Additionally, the company faced a significant revenue adjustment of $43 million linked to its transition to the Kodiak revenue cycle management platform, contributing to concerns about accounts receivable collectability and a conservative outlook on future revenue generation. Moreover, revised estimates indicate lowered EBITDA projections for 2025 and 2026, reflecting ongoing challenges related to denial reductions and professional fee headwinds, thus implying minimal or negative EBITDA growth moving forward.

ARDT has been analyzed by 12 analysts, with a consensus rating of Buy. 25% of analysts recommend a Strong Buy, 42% recommend Buy, 25% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardent Health Partners LLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardent Health Partners LLC (ARDT) Forecast

Analysts have given ARDT a Buy based on their latest research and market trends.

According to 12 analysts, ARDT has a Buy consensus rating as of Apr 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardent Health Partners LLC (ARDT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.